Considering EZH2's function, we speculate that EZH2 may directly silence the expression of SLC12A5. Finally, we analyzed the expression and prognosis of SLC12A5 in TCGA and CGGA datasets, revealing low expression of SLC12A5 in gliomas, particularly in GBM (Fig. S1c). The gene discussed is SLC12A5; the disease is central nervous system cancer.